Last updated: February 24, 2026
What is the drug associated with NDC 00025-0061?
NDC 00025-0061 corresponds to Eliquis (apixaban), an oral anticoagulant indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation, treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for thromboprophylaxis post-hip or knee replacement.
How is the current market structured?
Eliquis, developed by Bristol-Myers Squibb and Pfizer, is a leading direct oral anticoagulant (DOAC), competing primarily with:
- Xarelto (rivaroxaban)
- Pradaxa (dabigatran)
- Savaysa (edoxaban)
The market growth stems from the increasing prevalence of atrial fibrillation, DVT, PE, and expanded indications.
What are the market dynamics influencing pricing?
Key factors:
-
Patent exclusivity and market entry:
Eliquis faced patent protections until recent legal challenges. Patent expiry in the U.S. was anticipated around 2026, with some biosimilar competition possibly emerging before 2024, depending on patent litigations and regulatory approvals.
-
Pricing trends:
List prices for Eliquis in the U.S. generally ranged between $450-$500 per month in 2022, varying by dosage and pharmacy discounts.
-
Reimbursement landscape:
Medicare and commercial payers negotiate formularies, often favoring drugs with lower net prices. Patient co-pay assistance programs also affect retail pricing.
Price comparisons:
| Drug |
Approximate Monthly Wholesale Price (2022) |
Market Status |
| Eliquis |
$450-$500 |
Leading DOAC with high market penetration |
| Xarelto |
$400-$470 |
Main competitor, slightly lower pricing |
| Pradaxa |
$430-$460 |
Slightly older, with less market share |
| Edoxaban |
$400-$430 |
Limited market presence |
Market share estimates (2022):
| Drug |
Market Share (Adjusted for prescriptions) |
| Eliquis |
45% |
| Xarelto |
35% |
| Pradaxa |
15% |
| Edoxaban |
5% |
What are price projections over the next five years?
Factors influencing future pricing:
- The entry of biosimilars and generics following patent expiration
- Payer and pharmacy benefit manager negotiations
- Manufacturing and supply chain costs
- Expanded indications (e.g., new formulations or combinations)
Projected pricing trends:
| Year |
Expected Wholesale Price Range |
Key Assumptions |
| 2023 |
$450 - $500 |
No biosimilar entry, stable patent protections |
| 2024 |
$350 - $400 |
Entry of first biosimilar, initial price reduction |
| 2025 |
$250 - $300 |
Increased biosimilar market penetration, discounts |
| 2026 |
$150 - $200 |
Major biosimilar approvals, widespread adoption, biosimilar price competition |
| 2027 |
$100 - $150 |
Continued biosimilar competition, market stabilization |
Cost reduction thresholds:
- Biosimilar market entry could reduce Eliquis prices by 50-65%
- Payer negotiations could further decrease net prices by 20-30%
Impact of biosimilars and generics
Eliquis's patent expiry anticipated in 2026 may trigger an influx of biosimilars and generic versions, exerting downward pressure on wholesale and retail prices. Biosimilar options may be priced 40-60% lower, possibly accelerating the decline in Eliquis's market share and pricing.
Market growth projection
The anticoagulant market is expected to grow at a compounded annual growth rate (CAGR) of approximately 8% through 2030, driven by:
- Rising cases of atrial fibrillation (~35 million globally)
- Aging population increasing DVT and PE incidences
- Expanded indications and use cases
Key takeaways
- Eliquis (NDC 00025-0061) maintained dominant market share (~45%) in 2022.
- Wholesale prices ranged between $450-$500 per month.
- Price projections indicate a decline to $150-$200 by 2026 due to biosimilar competition.
- Patent expiration around 2026 will likely catalyze major price reductions.
- The overall anticoagulant market is expanding at an 8% CAGR, driven by demographic trends.
FAQs
1. When is patent expiration for Eliquis expected?
Patent rights are expected to expire in 2026, leading to biosimilar entry.
2. How will biosimilar competition affect Eliquis pricing?
Biosimilars are projected to reduce wholesale prices by 40-60%, with more significant discounts expected upon widespread adoption.
3. Are there existing biosimilars approved for Eliquis?
As of 2023, biosimilars for Eliquis are in development but not yet approved; generic formulations are more common for older anticoagulants.
4. What are the main drivers of growth in the anticoagulant market?
Growing prevalence of atrial fibrillation, aging populations, and expanded indications contribute to market growth.
5. How do payer negotiations impact Eliquis pricing?
Payers negotiate rebates and formulary placements, often leading to lower net prices and co-pay assistance programs for patients.
References
- U.S. Food and Drug Administration. (2022). NDC Directory. [online] Available at: https://www.fda.gov/drugs/ndc-directory
- IQVIA. (2022). National Prescription Audit.
- EvaluatePharma. (2022). World Preview of Cardiovascular Drugs.
- Bloomberg Intelligence. (2023). Biopharma Market Forecasts.
- Patent Expiry Data. (2023). Generic Drug Market Watch.
